CATX Quote, Financials, Valuation and Earnings

Retractable Technologies has a net margin of -- compared to Perspective Therapeutics's net margin of -126.59%. Perspective Therapeutics's return on equity of -- beat Retractable Technologies's return on equity of -26.39%.

Perspective Therapeutics has a consensus price target of $14.1071, signalling upside risk potential of 252.68%. On the other hand Retractable Technologies has an analysts' consensus of -- which suggests that it could fall by --. Given that Perspective Therapeutics has higher upside potential than Retractable Technologies, analysts believe Perspective Therapeutics is more attractive than Retractable Technologies.

Perspective Therapeutics has a beta of 1.177, which suggesting that the stock is 17.701% more volatile than S&P 500. In comparison Retractable Technologies has a beta of 1.357, suggesting its more volatile than the S&P 500 by 35.696%.

Perspective Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Retractable Technologies offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Perspective Therapeutics pays -- of its earnings as a dividend. Retractable Technologies pays out -1.94% of its earnings as a dividend.

Perspective Therapeutics quarterly revenues are --, which are smaller than Retractable Technologies quarterly revenues of $8.3M. Perspective Therapeutics's net income of -$18.2M is lower than Retractable Technologies's net income of -$10.5M. Notably, Perspective Therapeutics's price-to-earnings ratio is -- while Retractable Technologies's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Perspective Therapeutics is 28.19x versus 0.59x for Retractable Technologies. Usually stocks with elevated PS ratios are considered overvalued.

VolitionRX has a net margin of -- compared to Perspective Therapeutics's net margin of -2201.34%. Perspective Therapeutics's return on equity of -- beat VolitionRX's return on equity of --.

Perspective Therapeutics has a consensus price target of $14.1071, signalling upside risk potential of 252.68%. On the other hand VolitionRX has an analysts' consensus of $2.94 which suggests that it could grow by 329.39%. Given that VolitionRX has higher upside potential than Perspective Therapeutics, analysts believe VolitionRX is more attractive than Perspective Therapeutics.

Perspective Therapeutics has a beta of 1.177, which suggesting that the stock is 17.701% more volatile than S&P 500. In comparison VolitionRX has a beta of 1.198, suggesting its more volatile than the S&P 500 by 19.798%.

Perspective Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. VolitionRX offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Perspective Therapeutics pays -- of its earnings as a dividend. VolitionRX pays out -- of its earnings as a dividend.

Perspective Therapeutics quarterly revenues are --, which are smaller than VolitionRX quarterly revenues of $246.4K. Perspective Therapeutics's net income of -$18.2M is lower than VolitionRX's net income of -$5.4M. Notably, Perspective Therapeutics's price-to-earnings ratio is -- while VolitionRX's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Perspective Therapeutics is 28.19x versus 47.19x for VolitionRX. Usually stocks with elevated PS ratios are considered overvalued.

Catheter Precision has a net margin of -- compared to Perspective Therapeutics's net margin of -2828.67%. Perspective Therapeutics's return on equity of -- beat Catheter Precision's return on equity of -137.84%.

Perspective Therapeutics has a consensus price target of $14.1071, signalling upside risk potential of 252.68%. On the other hand Catheter Precision has an analysts' consensus of -- which suggests that it could grow by 747.46%. Given that Catheter Precision has higher upside potential than Perspective Therapeutics, analysts believe Catheter Precision is more attractive than Perspective Therapeutics.

Perspective Therapeutics has a beta of 1.177, which suggesting that the stock is 17.701% more volatile than S&P 500. In comparison Catheter Precision has a beta of -0.724, suggesting its less volatile than the S&P 500 by 172.434%.

Perspective Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Catheter Precision offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Perspective Therapeutics pays -- of its earnings as a dividend. Catheter Precision pays out -- of its earnings as a dividend.

Perspective Therapeutics quarterly revenues are --, which are smaller than Catheter Precision quarterly revenues of $143K. Perspective Therapeutics's net income of -$18.2M is lower than Catheter Precision's net income of -$4M. Notably, Perspective Therapeutics's price-to-earnings ratio is -- while Catheter Precision's PE ratio is 0.40x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Perspective Therapeutics is 28.19x versus 2.71x for Catheter Precision. Usually stocks with elevated PS ratios are considered overvalued.

Xtant Medical Holdings has a net margin of -- compared to Perspective Therapeutics's net margin of 0.18%. Perspective Therapeutics's return on equity of -- beat Xtant Medical Holdings's return on equity of -26.62%.

Perspective Therapeutics has a consensus price target of $14.1071, signalling upside risk potential of 252.68%. On the other hand Xtant Medical Holdings has an analysts' consensus of $1.75 which suggests that it could grow by 171.99%. Given that Perspective Therapeutics has higher upside potential than Xtant Medical Holdings, analysts believe Perspective Therapeutics is more attractive than Xtant Medical Holdings.

Perspective Therapeutics has a beta of 1.177, which suggesting that the stock is 17.701% more volatile than S&P 500. In comparison Xtant Medical Holdings has a beta of -0.139, suggesting its less volatile than the S&P 500 by 113.918%.

Perspective Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Xtant Medical Holdings offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Perspective Therapeutics pays -- of its earnings as a dividend. Xtant Medical Holdings pays out -- of its earnings as a dividend.

Perspective Therapeutics quarterly revenues are --, which are smaller than Xtant Medical Holdings quarterly revenues of $32.9M. Perspective Therapeutics's net income of -$18.2M is lower than Xtant Medical Holdings's net income of $58K. Notably, Perspective Therapeutics's price-to-earnings ratio is -- while Xtant Medical Holdings's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Perspective Therapeutics is 28.19x versus 0.72x for Xtant Medical Holdings. Usually stocks with elevated PS ratios are considered overvalued.